Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06731218
PHASE1

Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus

Sponsor: Hangzhou Reprogenix Bioscience, Inc

View on ClinicalTrials.gov

Summary

This Phase I clinical trial is a single-center, single-arm, open-label study aimed at evaluating the safety and therapeutic efficacy of RGB-5088 islet cell transplantation in patients with Type 1 Diabetes Mellitus.

Official title: A Single-Center, Single-Arm, Open-Label Phase I Clinical Trial Evaluating the Safety and Efficacy of RGB-5088 Islet Cell Injection in the Treatment of Type 1 Diabetes Mellitus

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-02-17

Completion Date

2031-12-31

Last Updated

2025-09-15

Healthy Volunteers

No

Interventions

BIOLOGICAL

RGB-5088

Transplantation under the anterior rectus sheath

Locations (1)

Tianjin First Center Hospital

Tianjin, Tianjin Municipality, China